This study was undertaken to determine the minimum effective dose of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, for the prevention of postoperative nausea and vomiting (PONV) after middle-ear surgery. In a randomized, double-blind, placebocontrolled trial, 120 women (ASA I) received placebo (saline) The incidence of nausea and vomiting after middleear surgery varies from 62 % to 80 % with no antiemetic treatment.
The incidence of nausea and vomiting after middleear surgery varies from 62 % to 80 % with no antiemetic treatment. [1] [2] [3] Granisetron, like ondansetron, is a selective antagonist of the 5 hydroxytryptamine type 3 (5-HT 3 ) receptor, and is effective for the treatment of emesis in patients receiving cytotoxic drugs. 4 Granisetron has a more potent and longer activity than ondansetron against emesis associated with chemotherapy. 5 We have recently shown that it reduces the incidence of nausea and vomiting after middle-ear surgery. 6 The present study was undertaken to determine the minimum effective dose of granisetron for the prevention of postoperative nausea and vomiting (PONV), in a randomized, double-blind comparison with placebo, in women undergoing middle-ear surgery.
Patients and methods
After obtaining institutional review board approval and informed consent, we studied 120 female patients (ASA I, aged 25-60 yr) undergoing middleear surgery (tympanoplasty or mastoidectomy). Patients with gastrointestinal disease, those with a history of motion sickness or previous PONV or both, those who were pregnant or menstruating, or who had taken antiemetics within 24 h before surgery were excluded from the study.
Patients received no preanaesthetic medication and, in a randomised, double-blind manner, a single dose of placebo (saline) ) was given. After operation, patients received indomethacin 50 mg as required when they complained of pain. After operation, all episodes of PONV (nausea, retching, vomiting) during the first 24 h after anaesthesia (that is, 0-3 h in the postanaesthetic unit and 3-24 h in the ward) were recorded by nursing staff unaware of which treatment patients had received. A complete response was defined as no PONV and no need for a rescue antiemetic. Details of any adverse effects throughout the study were also recorded by a follow-up nurse who interviewed the patients.
Statistical analyses of data obtained were performed by one-way analysis of variance (ANOVA) with Bonferroni correction for multiple comparison, the chi-square test or Fisher's exact probability test, as appropriate. P:0.05 was considered significant. All values were expressed as mean (SD), median (ranges) or number (%). We set ␣:0.05 and ␤:0.8, and used a large magnitude of effect (effective size 0.8) to estimate a sufficient sample size. The analysis showed that 30 patients per group would be sufficient.
Results
The treatment groups were comparable with regard to patient characteristics and types of operation (table 1) (table 2) . The most common adverse events in the four groups were headache and dizziness (table 3) . There were no differences in the incidence of these events during the first 3 h and the next 21 h after anaesthesia among the treatment groups (that is, the incidence was 17-20 % in each group).
Discussion
Middle-ear surgery (tympanoplasty or mastoidectomy) is associated with a relatively high incidence of PONV.
1-3 Previous studies found the incidence of PONV to be between 62 % and 80 % in patients undergoing general anaesthesia for middle-ear 5 (17) Headache 2 (7) 2 (7) 2 (7) 2 (7) Dizziness 2 (7) 2 (7) 2 (7) 2 (7) Others (constipation, muscle pain) 2 (7) 2 (7) 1 (3) 1 (3) 3-24 h after anaesthesia Any adverse efects 6 (20) 5 (17) 5 (17) 6 (20) Headache 3 (10) 2 (7) 2 (7) 3 (10) Dizziness 2 (7) 2 (7) 2 (7) 2 (7) Others (constipation, muscle pain)
surgery. [1] [2] [3] The incidence of PONV (no complete response) in this study was approximately 60 % in patients who had received placebo, and was in accordance with our previous study in this population. 6 The aetiology of PONV after middle-ear surgery is complex and depends on several factors, which include patient characteristics, types of surgery, anaesthetic technique and postoperative pain. 7 Patient-related factors are age, sex, obesity and a history of motion sickness or previous PONV or both. Surgical factors include an increased middle-ear pressure caused by nitrous oxide. 3 In the present study, however, the treatment groups were comparable with respect to patient characteristics, surgical procedure, anaesthetics administered and analgesics used after operation. In addition, no pressure was generated in the middle-ear from diffusion of nitrous oxide, which was replaced by air before closing of tympanic membrane. Therefore, the difference in the incidence of PONV among the groups can be attributed to the difference in dose of granisetron administered. Granisetron has been reported to be effective for the treatment of emesis induced by cancer chemotherapy. 4 In previous studies we have demonstrated that granisetron 40 g kg 91 reduces the incidence of PONV after middle-ear surgery and gynaecological surgery. 6 8 For the treatment of emesis induced by cancer therapy, the effective dose of granisetron is between 40 g kg 91 and 80 g kg
91
. 9 We demonstrated in the present study that granisetron 40 g kg 91 was as effective as granisetron 100 g kg 91 in the prevention of PONV, and that antiemetic efficacy of each dose was superior to that of placebo during the periods 0-3 h and 3-24 h (P:0.001). No difference in a complete response (no PONV, no rescue) was observed between patients who had received placebo and those who had received granisetron 20 g kg
. These results suggest that granisetron 40 g kg 91 is the minimum effective dose for the prevention of PONV after middle-ear surgery. Adverse events observed in this study were relatively mild, and there was no difference in the incidence of adverse effects, such as headache and dizziness, among the four groups.
The use of new antiemetics (for example, 5-HT 3 receptor antagonists) has been recently criticized because of its high cost. 10 Our hospital pharmacy pays $103 for granisetron 3 mg, and the drug is much more expensive than other antiemetics (for example, $1.8 for droperidol 2.5 ma, $0.6 for metoclopramide 10 mg). However, use of these cheaper antiemetics has been limited because of their side effects, which include excessive sedation and extra pyramidal symptoms. 7 Furthermore, on the basis of our results, the use of a lower dose (40 g kg
) would reduce the cost of granisetron. In conclusion, granisetron 40 g kg 91 is an effective antiemetic for the prevention of PONV after middle-ear surgery. Increasing the dose to 100 g kg 91 provides no demonstrable benefit in reducing the incidence of PONV.
